HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LDN-OSU-0212320

a CYP11B1 inhibitor; activates translation of glutamate transporter EAAT2; structure in first source

Also Known As:

LDN-212320

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - LDN-OSU-0212320: 3
  - Pyridazines: 11
    - LDN-OSU-0212320: 3

Experts

1.	Chen, Lixue: 1 article (11/2020)
2.	Fei, Zhaoyang: 1 article (11/2020)
3.	Liang, Jie: 1 article (11/2020)
4.	Qin, Guangcheng: 1 article (11/2020)
5.	Wang, Jiang: 1 article (11/2020)
6.	Zhang, Dunke: 1 article (11/2020)
7.	Zhou, Jiying: 1 article (11/2020)
8.	Zhou, Xue: 1 article (11/2020)
9.	Alotaibi, Ghallab: 1 article (04/2019)
10.	Rahman, Shafiqur: 1 article (04/2019)

Related Diseases

1.	Hyperalgesia 05/16/2023 - "Pretreatment with LDN-212320 (20 mg/kg) significantly reduced the CFA-induced tactile allodynia and thermal hyperalgesia. " 05/16/2023 - "Overall, these results suggest that LDN-212320 prevents CFA-induced allodynia and hyperalgesia by upregulating astroglial GLT-1 and CX43 expression and decreasing microglial activation in the hippocampus and ACC. " 11/01/2020 - "To understand the effect of EAAT2 on central sensitization of CM, mechanical and thermal hyperalgesia and central sensitization-associated proteins were examined after administration of LDN-212320. " 11/01/2020 - "In our study, elevated glutamate concentration and decreased EAAT2 expression were found in the trigeminal nucleus caudalis of CM rats, administration of LDN-212320 greatly up-regulated the protein expression of EAAT2, alleviated hyperalgesia, decreased the concentration of glutamate and the activation of astrocytes. "
2.	Nociceptive Pain 04/01/2019 - "These results suggest that the GLT-1 activator LDN-212320 prevents nociceptive pain by upregulating astroglial GLT-1 expression in the hippocampus and ACC. " 04/01/2019 - "We evaluated the effects of LDN-212320 in formalin-induced nociceptive pain model. "
3.	Pain (Aches) 05/16/2023 - "Therefore, LDN-212320 could be developed as a novel therapeutic drug candidate for chronic inflammatory pain."

Related Drugs and Biologics

1.	Glutamic Acid (Glutamate)
2.	Proteins (Proteins, Gene)
3.	Connexin 43 (Connexin43)
4.	Formaldehyde (Formol)